Bioverativ Inc. (delisted) News - BIVV

Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders...

Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders...

Bioverativ Inc. (NASDAQ: BIVV) announced today that it will present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference. The event...

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...

Bioverativ Inc. (NASDAQ: BIVV) announced today that it will present at the Credit Suisse 2017 Healthcare Conference. The event will be...

- Presentations will highlight Bioverativ’s scientific innovation in hemophilia, cold agglutinin disease, sickle cell disease and...

Positive results seen in study participants regardless of prior treatment regimen, severity of joint damage or target joints First...

Table of Contents UNITED STATES SECURITIES AND...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Third quarter revenues up 27.2% year-over-year driven by continued hemophilia franchise momentum and strong commercial execution Third...

Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy...

Bioverativ Inc. (NASDAQ: BIVV) will report its financial results for the third quarter ending September 30, 2017, on Thursday, October 26...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Bicycle to receive an upfront payment of $10 million, with potential for future milestones Bioverativ Inc. (NASDAQ: BIVV), a global...